scholarly article | Q13442814 |
review article | Q7318358 |
P50 | author | Alan G Kabat | Q64819592 |
Jodi Luchs | Q89536538 | ||
P2093 | author name string | Paul Karpecki | |
Bridgitte Shen Lee | |||
Jason Bacharach | |||
P2860 | cites work | Over the counter (OTC) artificial tear drops for dry eye syndrome | Q24186110 |
Controlled ocular drug delivery with nanomicelles | Q27012087 | ||
Autologous serum eye drops for dry eye. | Q30235522 | ||
Patient reported differences in dry eye disease between men and women: impact, management, and patient satisfaction | Q35010238 | ||
Topical, Aqueous, Clear Cyclosporine Formulation Design for Anterior and Posterior Ocular Delivery | Q35565484 | ||
Long-term Natural History of Dry Eye Disease from the Patient's Perspective | Q36494967 | ||
Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study | Q36877000 | ||
TFOS DEWS II Diagnostic Methodology report | Q38652978 | ||
TFOS DEWS II iatrogenic report. | Q38652981 | ||
TFOS DEWS II pathophysiology report | Q38652987 | ||
TFOS DEWS II Epidemiology Report | Q38652994 | ||
Cyclosporine A delivery to the eye: A comprehensive review of academic and industrial efforts | Q39185845 | ||
TFOS DEWS II Management and Therapy Report | Q39453364 | ||
Dietary Supplementation with a Combination of Lactoferrin, Fish Oil, and Enterococcus faecium WB2000 for Treating Dry Eye: A Rat Model and Human Clinical Study | Q40078017 | ||
Predictors of Discordance between Symptoms and Signs in Dry Eye Disease | Q40407061 | ||
Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group | Q41730611 | ||
Epidemiology of discordance between symptoms and signs of dry eye. | Q47642988 | ||
The efficacy of topical 0.05 % cyclosporine A in patients with dry eye disease associated with Sjögren's syndrome. | Q50480678 | ||
Migration of Cosmetic Products into the Tear Film. | Q51048830 | ||
Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye. | Q52608828 | ||
One-year efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease. | Q53836361 | ||
The Correlation between Daily Lens Wear Duration and Dry Eye Syndrome. | Q55115758 | ||
A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease | Q57484944 | ||
Investigating the effect of eye cosmetics on the tear film: current insights | Q57593846 | ||
Oral Alcohol Administration Disturbs Tear Film and Ocular Surface | Q58336800 | ||
Self-reported compliance with topical cyclosporine emulsion 0.05% and onset of the effects of increased tear production as assessed through patient surveys | Q79526746 | ||
n-3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease | Q88350776 | ||
A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease | Q91291525 | ||
Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Corneal Staining in Patients With Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and Phase 3 Studies | Q91885064 | ||
A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease | Q92970826 | ||
Effect of calorie restriction on change in lacrimal gland with age | Q95382642 | ||
P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
P6216 | copyright status | copyrighted | Q50423863 |
P921 | main subject | eye disease | Q3041498 |
P304 | page(s) | 119-126 | |
P577 | publication date | 2020-01-14 | |
P1433 | published in | Clinical Ophthalmology | Q5133782 |
P1476 | title | Managing Dry Eye Disease and Facilitating Realistic Patient Expectations: A Review and Appraisal of Current Therapies | |
P478 | volume | 14 |
Search more.